0
Skip to Content
Scinai
Scinai
Scinai
Team
Careers
PIPELINE
Targeted Intradermal IL-17
Systemic Bi-Specific IL-17
CDMO Services
Aseptic Processing
cGMP Manufacturing
Process development & scale-up
Analytical Methods Development
Quality and Regulatory Standards
Expert Insights on Drug Development
Scinai BioServices Inc.
Investor Relations
Shareholders Meeting
Knowledge Center
Press Releases
In The News
Contact us
Scinai
Scinai
Scinai
Team
Careers
PIPELINE
Targeted Intradermal IL-17
Systemic Bi-Specific IL-17
CDMO Services
Aseptic Processing
cGMP Manufacturing
Process development & scale-up
Analytical Methods Development
Quality and Regulatory Standards
Expert Insights on Drug Development
Scinai BioServices Inc.
Investor Relations
Shareholders Meeting
Knowledge Center
Press Releases
In The News
Contact us
Folder: ABOUT
Back
Scinai
Team
Careers
Folder: R & D
Back
PIPELINE
Targeted Intradermal IL-17
Systemic Bi-Specific IL-17
Folder: CDMO
Back
CDMO Services
Aseptic Processing
cGMP Manufacturing
Process development & scale-up
Analytical Methods Development
Quality and Regulatory Standards
Expert Insights on Drug Development
Scinai BioServices Inc.
Folder: INVESTORS
Back
Investor Relations
Shareholders Meeting
Folder: RESOURCES
Back
Knowledge Center
Folder: NEWS & EVENTS
Back
Press Releases
In The News
Contact us

Biologics Development in Immunology and Inflammation — Featuring Amir Reichman, CEO of Scinai Immunotherapeutics

Feb 21
Written by Josh Phillipson
Josh Phillipson
Previous
Previous

“This CEO Is Using Alpaca DNA To Fight Inflammation & A Lot More!” Scinai Immunotherapeutics $SCNI ceo amir reichman in an interview with adam sarhan on the smart money circle show
Next
Next

Biopharma Company Sees Success In Trial For Psoriasis Jab

Investors


News and Events

Contact

About Us


Science


CDMO Services

Copyright 2025 Scinai Immunotherapeutics Ltd. All Rights Reserved | Terms of Use | Privacy Policy